10x Genomics Inc-Class A has 19 Schedule 13D or 13G filings on record since 2025-07-16. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Fmr LLC | 15.6% | 18,543,562 | SCHEDULE 13G/A, 2026-03-06 | 2026-02-27 |
| T. Rowe Price Associates, Inc. | 11.7% | 14,044,020 | SCHEDULE 13G, 2026-09-08 | 2026-08-31 |
| ARK Investment Management LLC | 8.56% | 10,003,058 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| BlackRock, Inc. | 7.6% | 8,496,636 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| Vanguard Portfolio Management | 5.93% | 6,981,683 | SCHEDULE 13G, 2026-04-28 | 2026-03-31 |
| Vanguard Capital Management | 5.24% | 6,166,597 | SCHEDULE 13G, 2026-04-29 | 2026-03-31 |
| Sumitomo Mitsui Trust Group, Inc. | 4.7% | 5,381,219 | SCHEDULE 13G/A, 2025-10-27 | 2025-09-30 |
| Amova Asset Management Americas, Inc. | 4.7% | 5,376,883 | SCHEDULE 13G/A, 2025-11-13 | 2025-09-30 |
| Millennium Management LLC | 2.7% | 3,060,859 | SCHEDULE 13G/A, 2025-08-12 | 2025-06-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-25 | 2026-03-13 |
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 7.6% | SCHEDULE 13G/A |
| 2025-07-31 | Sumitomo Mitsui Trust Group, Inc. | 5.4% | SCHEDULE 13G |
| 2025-08-06 | Fmr LLC | 8.8% | SCHEDULE 13G/A |
| 2025-08-07 | Fmr LLC | 10.3% | SCHEDULE 13G/A |
| 2025-08-12 | Millennium Management LLC | 2.7% | SCHEDULE 13G/A |
| 2025-08-13 | Nikko Asset Management Americas, Inc. | 5.4% | SCHEDULE 13G |
| 2025-10-27 | Sumitomo Mitsui Trust Group, Inc. | 4.7% | SCHEDULE 13G/A |
| 2025-10-30 | The Vanguard Group | 11.6% | SCHEDULE 13G/A |
| 2025-11-04 | ARK Investment Management LLC | 10.39% | SCHEDULE 13G/A |
| 2025-11-05 | Fmr LLC | 8.1% | SCHEDULE 13G/A |
| 2025-11-13 | Amova Asset Management Americas, Inc. | 4.7% | SCHEDULE 13G/A |
| 2026-01-08 | Fmr LLC | 10.8% | SCHEDULE 13G/A |
| 2026-03-06 | Fmr LLC | 15.6% | SCHEDULE 13G/A |
| 2026-03-24 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-03-25 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-28 | Vanguard Portfolio Management | 5.93% | SCHEDULE 13G |
| 2026-04-29 | Vanguard Capital Management | 5.24% | SCHEDULE 13G |
| 2026-08-14 | ARK Investment Management LLC | 8.56% | SCHEDULE 13G/A |
| 2026-09-08 | T. Rowe Price Associates, Inc. | 11.7% | SCHEDULE 13G |
Tools for this story
Each opens in a new tab, filled in for 10x Genomics Inc-Class A. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.